The expanding landscape of GLP-1 medicines

Nat Med. 2026 Jan 2. doi: 10.1038/s41591-025-04124-5. Online ahead of print.ABSTRACTGlucagon-like peptide-1 medicines are being prescribed to growing numbers of patients worldwide, for type 2 diabetes, obesity and associated comorbidities, including cardiovascular disease, peripheral artery disease

D Daniel J Drucker

Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial

Lancet Haematol. 2026 Jan;13(1):e30-e40. doi: 10.1016/S2352-3026(25)00298-4.ABSTRACTBACKGROUND: Iberdomide is an oral cereblon E3 ligase modulator with higher affinity to cereblon than immunomodulatory drugs, leading to improved direct anti-myeloma activity and enhanced immunostimulatory effects. We

C Charlotte L B M Korst

The health effects of diaphragmatic breathing: a systematic review

Complement Ther Med. 2025 Dec 31:103317. doi: 10.1016/j.ctim.2025.103317. Online ahead of print.ABSTRACTBACKGROUND: Diaphragmatic breathing (DB) is widely used clinically, but a comprehensive synthesis of randomized controlled trial (RCT) evidence on its health effects is lacking. This systematic re

C Chan-Young Kwon

Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know

Surv Ophthalmol. 2025 Dec 31:S0039-6257(25)00236-X. doi: 10.1016/j.survophthal.2025.12.007. Online ahead of print.ABSTRACTInitially designed for the treatment of type-2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1RA) are multifaceted agents with promising neuroprotective and anti-infla

S Suraj Bala